BlackRock's Rick Rieder: I Think Rates Can Come Down
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
a minute ago
- Forbes
New Study: Switching To 4 Day Workweek Reduces Burnout
Companies that switched to a 4 day workweek, with no reduction in pay, saw major improvements in their workers' well-being, according to a new study published in Nature Human Behaviour earlier this month. Led by Boston College sociologists Wen Fan and Juliet Schor, the study was the largest of its kind, involving 2,896 employees across 141 organizations in the US, the UK, Canada, Ireland, Australia, and New Zealand. 'When workers want to deliver the same productivity, they might work very rapidly to get the job done, and their well-being might actually worsen,' Fan told Nature. 'But that's not what we found.' Compared to a control group of 300 workers at 12 companies that kept a traditional 5-day workweek, the firms that switched to a 4-day workweek instead showed 'improvements in burnout, job satisfaction, mental health and physical health.' Moreover, the individual workers themselves reported gains in work ability as well as 'reduced sleep problems and decreased fatigue.' Based on the study's results, the authors concluded that 'income-preserving 4-day workweeks are an effective organizational intervention for enhancing workers' well-being.' Before the participating companies began their six-month trial period of reduced work hours, the businesses were given approximately eight weeks to streamline their organizational processes and restructure workflow. So to maintain their productivity, many companies participating in the study eliminated superfluous meetings and other time-wasting, if deeply ingrained, activities. Notably, 90% of the companies that participated in the study ultimately decided to keep their 4-day workweeks, strongly implying that the benefits of a shortened workweek outweighed any potential downsides or losses in productivity. The findings in Nature Human Behaviour are largely consistent with previous trials and pilot programs conducted at other companies around the world. Combined, these studies could even provide some empirical evidence for the oft-cited Parkinson's Law: 'Work expands so as to fill the time available for its completion.' Given these promising results, policymakers have started to take notice. Last year, Sen. Bernie Sanders (I-VT) introduced the Thirty-Two Hour Workweek Act (S. 3947). True to its name, the bill would amend the Fair Labor Standards Act to reduce the standard workweek from 40 hours to 32 hours, with no corresponding loss in pay. If enacted, the bill would have marked the first reduction in the federal workweek since 1940, when it was lowered from 44 hours to 40 hours. 'Moving to a 32-hour workweek with no loss of pay is not a radical idea,' Sen. Sanders said in a statement when he released the bill. 'The financial gains from the major advancements in artificial intelligence, automation, and new technology must benefit the working class, not just corporate CEOs and wealthy stockholders on Wall Street. It is time to reduce the stress level in our country and allow Americans to enjoy a better quality of life. It is time for a 32-hour workweek with no loss in pay.'
Associated Press
a minute ago
- Associated Press
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Neogen Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neogen Corporation (NASDAQ: NEOG) between January 5, 2023 and June 3, 2025, inclusive (the 'Class Period'), of the important September 16, 2025 lead plaintiff deadline. SO WHAT: If you purchased Neogen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Neogen class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 16, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements which led investors to believe that the integration was progressing smoothly when the opposite was true. At the beginning of the Class Period, defendants touted that the integration process was 'off to a great start' and that Neogen 'delivered solid core growth in both of our segments and, notably, a level of profitability well ahead of where the company was prior to the acquisition.' In addition, while Neogen admitted that certain 'inefficiencies' arose as a result of the integration process, defendants downplayed them assuring investors, 'we have our arms around the key issues and are fully committed to resolving them in the near future.' When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Neogen class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Associated Press
a minute ago
- Associated Press
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ('Revive' or the 'Company') (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is proposing to arrange a private placement offering of up to 30,952,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of up to $650,000, and to settle $67,400 owing pursuant to an arm's length note payable by the issuance of 3,209,523 units, at a price of $0.021 per unit, being the same issue price and security being offering pursuant to the private placement. Each unit will consist of one common share of the Company and one common share purchase warrant. Each warrant will entitle the holder to acquire one common share at an exercise price of $0.05 for a period of 36 months following the closing. The issue price per unit is based upon the 20-day VWAP of the shares traded on the CSE at the time that the Company obtained price protection. The gross proceeds from the private placement offering will be used for working capital and payment of certain trade payables. The proposed private placement may close in one or more tranches. The Company believes that it is desirable to settle the outstanding note payable by the issuance of securities in order to preserve the Company's cash for ongoing operations. Closing of the private placement and the debt settlement is subject to customary closing conditions and the Company intends to close as soon as practicable. All of the securities will be subject to a hold period of four months and one day from the date of issuance. About Revive Therapeutics Ltd. Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives like Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations, positioning for rapid advancement and market entry. Currently, our efforts are concentrated on unlocking the vast potential of Bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing our Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science. For more information, visit For more information, please contact: Michael Frank Chief Executive Officer Revive Therapeutics Ltd. Tel: 1 888 901 0036 Email: [email protected] Website: Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement
